Paradoxical effects of ethoxidine, a topoisomerase I inhibitor, in the cellular processes leading to angiogenesis on endothelial cells

Carcinogenesis

Volumn 32, Issue 3, 2011, Pages 286-295

  Clere, Nicolas ^a   Faure, Sébastien ^a   Helesbeux, Jean Jacques ^b   Duval, Olivier ^b   Andriantsitohaina, Ramaroson ^a  

^a UNIVERSITÉ D'ANGERS   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ETHOXIDINE; GELATINASE A; NITRIC OXIDE; SUPEROXIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TEMPERATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 79952308611     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq260     Document Type: Article

References (46)

1. Risau,W. (1997) Mechanisms of angiogenesis. Nature, 386, 671-674.
2. Reynolds,L. et al. (1992) Angiogenesis in the female reproductive system. FASEB J., 6, 886-892.
3. Folkman,J. (1995) Seminars in medicine of the Beth Israel hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med., 333, 1757-1763.
4. Folkman,J. (1990) What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst., 82, 4-6.
5. Gimbrone,M.J. et al. (1972) Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med., 136, 261-276.
6. Adams,R. et al. (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol., 8, 464-478.
7. Carmeliet,P. (2005) Angiogenesis in life, disease and medicine. Nature, 438, 932-936.
8. Wang,J. (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol., 3, 430-440.
9. Larsen,A. et al. (1999) DNA topoisomerase I in oncology: dr Jekyll or Mr Hyde? Pathol. Oncol. Res., 5, 171-178.
10. Jones,C. et al. (1997) Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells. Cancer Chemother. Pharmacol., 40, 475-483.
11. Lynch,M. et al. (2001) Synthesis, biological activity and comparative analysis of DNA binding affinities and human DNA topoisomerase I inhibitory activities of novel 12-alkoxy-benzo[c]phenanthridinium salts. Bioorg. Med. Chem. Lett., 11, 2643-2646.
12. Mackay,S. et al. (1998) The effect of 12-alkoxy modification on the in vitro antileukaemic activity of N-methyl 2,3,8,9-tetramethoxybenzo[c]phenanthridinium salts. Anticancer Drug Des., 13, 797-813.
13. Devy,J. et al. (2010) The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity. Invest. New Drugs, in press.
14. Soret,J. et al. (2003) Altered serine/arginine-rich protein phosphorylation and exonic enhancer-dependent splicing in Mammalian cells lacking topoisomerase I. Cancer Res., 63, 8203-8211.
15. Eisenreich,A. et al. (2009) Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells. Circ. Res., 104, 589-599.
16. Clements,M. et al. (1999) Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother. Pharmacol., 44, 411-416.
17. O'Leary,J. et al. (1999) Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin. Cancer Res., 5, 181-187.
18. Puppo,M. et al. (2008) Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Mol. Cancer Ther., 7, 1974-1984.
19. Eisenreich,A. et al. (2008) Effects of the Cdc2-like kinase-family and DNA topoisomerase I on the alternative splicing of eNOS in TNF-alphastimulated human endothelial cells. Biol. Chem., 389, 1333-1338.
20. Houghton,P. et al. (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res., 64, 2333-2337.
21. Huang,M. et al. (2007) Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Clin. Cancer Res., 13, 1298-1307.
22. Favot,L. et al. (2003) Involvement of cyclin-dependent pathway in the inhibitory effect of delphinidin on angiogenesis. Cardiovasc. Res., 59, 479-487.
23. Łuczak,K. et al. (2004) Low concentration of oxidant and nitric oxide donors stimulate proliferation of human endothelial cells in vitro. Cell Biol. Int., 28, 483-486.
24. Fleury,F. et al. (2000) Molecular determinants of site-specific inhibition of human DNA topoisomerase I by fagaronine and ethoxidine. Relation to DNA binding. J. Biol. Chem., 275, 3501-3509.
25. Folkman,J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285, 1182-1186.
26. Hanahan,D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
27. Soeda,S. et al. (2000) Oversulfated fucoidan inhibits the basic fibroblast growth factor-induced tube formation by human umbilical vein endothelial cells: its possible mechanism of action. Biochim. Biophys. Acta, 1497, 127-134.
28. Beppu,K. et al. (2005) Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res., 65, 4775-4781.
29. Lin,S. et al. (2009) Topotecan inhibits cancer cell migration by downregulation of chemokine CC motif receptor 7 and matrix metalloproteinases. Acta Pharmacol. Sin., 30, 628-636.
30. Nakashio,A. et al. (2002) Topotecan inhibits VEGF-and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. Int. J. Cancer, 98, 36-41.
31. Radisavljevic,Z. et al. (2000) Vascular endothelial growth factor upregulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/Nitric oxide pathway and modulates migration of brain microvascular endothelial cells. J. Biol. Chem., 275, 20770-20774.
32. Ziche,M. et al. (2009) Molecular regulation of tumour angiogenesis by nitric oxide. Eur. Cytokine Netw., 20, 164-170.
33. Park,H. et al. (2009) Neuromedin B induces angiogenesis via activation of ERK and Akt in endothelial cells. Exp. Cell Res., 315, 3359-3369.
34. Gerber,H. et al. (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3#-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem., 273, 30336-30343.
35. Daher,Z. et al. (2010) Vascular endothelial growth factor Receptor-2 Activates ADP-ribosylation factor 1 to promote endothelial nitric-oxide synthase activation and nitric oxide release from endothelial cells. J. Biol. Chem., 285, 24591-24599.
36. Jiang,B. et al. (2000) Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl Acad. Sci. USA, 97, 1749-1753.
37. Griffioen,A. et al. (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev., 52, 237-268.
38. Ziche,M. et al. (1997) Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factorinduced angiogenesis. J. Clin. Invest., 99, 2625-2634.
39. Bellou,S. et al. (2009) VEGF autoregulates its proliferative and migratory ERK1/2 and p.38 cascades by enhancing the expression of DUSP1 and DUSP5 phosphatases in endothelial cells. Am. J. Physiol. Cell Physiol., 297, C1477-C1489.
40. Pignochino,Y. et al. (2009) Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol. Cancer, 8, 118.
41. Chua,C. et al. (1998) Upregulation of vascular endothelial growth factor by H2O2 in rat heart endothelial cells. Free Radic. Biol. Med., 25, 891-897.
42. Vepa,S. et al. (1999) Hydrogen peroxide stimulates tyrosine phosphorylation of focal adhesion kinase in vascular endothelial cells. Am. J. Physiol., 277, L150-L158.
43. Shono,T. et al. (1996) Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol. Cell Biol., 16, 4231-4239.
44. Servettaz,A. et al. (2009) Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J. Immunol., 182, 5855-5864.
45. Rapisarda,A. et al. (2004) Topoisomerase I-mediated inhibition of hypoxiainducible factor 1: mechanism and therapeutic implications. Cancer Res., 64, 1475-1482.
46. Hashimoto,K. et al. (2010) Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol. Cancer Ther., 9, 996-1006.